1613552-03-6

Basic information

• Product Name: [(S)-1-((S)-2-{(2S,4S)-4-amino-2-[(R)-(1,2,3,4-tetrahydro-naphthalen-1-yl)carbamoyl]-pyrrolidin-1-yl}-1-cyclohexyl-2-oxo-ethylcarbamoyl)-ethyl]-methyl-carbamic acid tert-butyl ester
• Synonyms: [(S)-1-((S)-2-{(2S,4S)-4-amino-2-[(R)-(1,2,3,4-tetrahydro-naphthalen-1-yl)carbamoyl]-pyrrolidin-1-yl}-1-cyclohexyl-2-oxo-ethylcarbamoyl)-ethyl]-methyl-carbamic acid tert-butyl ester
• CAS NO: 1613552-03-6
• Molecular Weight: 583.772
• Mol File: 1613552-03-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: [(S)-1-((S)-2-{(2S,4S)-4-amino-2-[(R)-(1,2,3,4-tetrahydro-naphthalen-1-yl)carbamoyl]-pyrrolidin-1-yl}-1-cyclohexyl-2-oxo-ethylcarbamoyl)-ethyl]-methyl-carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [(S)-1-((S)-2-{(2S,4S)-4-amino-2-[(R)-(1,2,3,4-tetrahydro-naphthalen-1-yl)carbamoyl]-pyrrolidin-1-yl}-1-cyclohexyl-2-oxo-ethylcarbamoyl)-ethyl]-methyl-carbamic acid tert-butyl ester(1613552-03-6)
• EPA Substance Registry System: [(S)-1-((S)-2-{(2S,4S)-4-amino-2-[(R)-(1,2,3,4-tetrahydro-naphthalen-1-yl)carbamoyl]-pyrrolidin-1-yl}-1-cyclohexyl-2-oxo-ethylcarbamoyl)-ethyl]-methyl-carbamic acid tert-butyl ester(1613552-03-6)

Safety Data

• Hazardous Substances Data: 1613552-03-6(Hazardous Substances Data)

Upstream product

• 949924-39-4 (9H-fluoren-9-yl)methyl ((3S,5S)-5-(((R)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)pyrrolidin-3-yl)carbamate trifluoroacetate salt 
• 1613552-02-5 {(3S,5S)-1-{(S)-2-[(S)-2-(tert-butoxycarbonyl-methyl-amino)-propionylamino]-2-cyclohexyl-acetyl}-5-[(R)-(1,2,3,4-tetrahydro-naphthalen-1-yl)carbamoyl]-pyrrolidin-3-yl}-carbamic acid 9H-fluoren-9-ylmethyl ester 
• 23357-46-2 (R)-1,2,3,4-Tetrahydro-1-naphthylamine 
• 174148-03-9 (2S,4S)-4-(9H-fluoren-9-ylmethoxycarbonylamino)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 

Relevant articles and documents

BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY

The present invention relates to compounds of formula (I) useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

DIMERIC COMPOUNDS

Disclosed are compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein Z, X, Q and R1 are as described in this application, and methods of using the compounds in the treatment of cancer.